SEC Form 4 · accession 0001179022-17-000074
GALECTIN THERAPEUTICS INC · GALT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Joel Lewis
Director
Period of report
Dec 14, 2017
Accepted (ET)
Dec 18, 2017 · 4:09 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001133416
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Dec 14, 2017 | A | 23,013 | $2.39 | A | 50,880 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock option (right to buy)F2 | $2.39 | Dec 14, 2017 | A | 62,250 | A | — | Dec 14, 2027 | Common stock | 62,250 | 62,250 | D |
Explanation of responses
- F1These restricted shares were issued in lieu of cash retainer and meeting fees of $55,000 for 2018. Restrictions on the shares lapse at a rate of 25% per calendar quarter in 2018.
- F2The options vest 100% on December 14, 2018.